SYK STRYKER CORP Insider Trading

SYK VP/CLO Robert S Fletcher sells 4,544 shares for $1.4M via scheduled 10b5-1 plan on 2026-05-28

Robert S Fletcher, VP and Chief Legal Officer of Stryker Corp, executed six separate sales totaling 4,544 shares for $1,394,409.11 on 2026-05-28, reducing his holdings by 30.0% from 15,126 to 10,582 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-26, meaning it was scheduled rather than a discretionary decision. The blended average sale price of $306.87 compares to the current price of $305.09, placing the stock 24.6% below its 52-week high of $404.87. His prior trades at SYK showed mixed near-term outcomes (−4.1% at 30 days in August 2025 and +2.9% at 30 days in May 2024), providing no clear directional signal about this filing's timing.

Ronda E Stryker (Director) sold 310,000 shares for $96.8M across 6 transactions on 2026-05-26; stock down 20.8% in 90 days.

Ronda E Stryker executed six separate sales totaling 310,000 shares for $96,792,668.92, reducing her holdings from 2,910,815 shares to 2,600,815 shares (-10.6%). The sales were priced between $310.77 and $315.11 with a blended average of $312.23. Over her cross-ticker history, this insider's 20 prior sells have produced an average 90-day return of -17.0% with a 90.00% well-timed rate; at SYK specifically, all 5 prior sales executed on 2026-02-05 resulted in negative 90-day returns ranging from -19.1% to -20.3%. The current stock price of $305.94 is down 24.4% from its 52-week high of $404.87 and down 20.8% over the past 90 days. This pattern of consistent pre-decline selling, when considered against the subsequent price deterioration and the company's elevated P/E of 35.17, reflects a track record of transaction timing aligned with subsequent weakness.

VP Chief HR Officer Kathryn Fink sold net 3,500 shares, disposing of over $7.2M in total value across multiple transactions on May 8–11.

Kathryn Fink, VP and Chief HR Officer at Stryker, executed a series of transactions that netted a reduction of approximately 3,500 shares while generating over $7.2M in gross disposition value. The activity mixed equity grants (exercised shares and withheld tax), but the net effect is a net sale as she reduced her stake. The stock is trading well below its 52-week high and down notably over the past month and quarter, presenting a backdrop of price weakness. Fink's prior sales history at Stryker shows a conflicting pattern: all five prior sales were well-timed in the very near term as the stock declined in the following month, but poorly timed over a longer three-month horizon as the stock recovered. This latest sale occurs as the company remains solidly profitable with growing revenue, though valued at a relatively elevated multiple. Notably, Fink has no record of open-market purchases in the prior three-year window—this filing adds her 13th and 14th open-market sales, deepening a consistent pattern of net disposition.

Director Ronda Stryker sold 500,000 SYK shares for $181.7M across 18 transactions Feb 4–5; 18.5% holdings reduction.

Director Ronda E. Stryker executed 18 separate sales totaling 500,000 shares for $181,719,268.58 on February 4–5, 2026, reducing her holdings by 500,000 shares (-18.5% vs pre-transaction holdings of 2,707,331 shares). The blended average sale price was $363.44, compared to the current market price of $358.29, placing the transaction 11.2% below the 52-week high of $403.53. Her prior trades at SYK (5 sells on 2025-11-06) showed a 0 of 5 well-timed rate at the 90-day mark, with average 90-day returns of +1.8% to +3.1%, meaning the stock subsequently rose after those prior sales. The company trades at a P/E of 46.53 with annual revenue growth of +10.2% and recent quarterly net income of $859.0M on $6.1B revenue. The scale and multi-tranche execution suggest a material reduction in her equity stake at relatively stable prices over two trading days.

Director Ronda Stryker sold 520,000 shares for $184.6M across 14 transactions over two days at blended average $355.01

Director Ronda E. Stryker executed 14 separate sales totaling 520,000 shares (520.0K shares) for $184,606,140.89 on November 5-6, 2025, reducing her stake from 3,222,108 shares (3.22M shares) to 2,702,108 shares (2.70M shares), a -16.1% reduction in holdings. The sales occurred at prices ranging from $349.95 to $359.79, with a blended average price of $355.01, just below the current price of $356.03. Her prior sales at SYK show consistent well-timing: all 5 of 5 prior sells at this ticker were well-timed at the 90-day mark (negative 90d returns ranging from -3.8% to -4.7%), suggesting systematic outperformance in the timing of exits. Her cross-ticker track record spans 20 prior sells with a 70.00% well-timed rate and a 90d average return of -2.8%, further supporting a pattern of disciplined sell execution. The scale of this transaction—$184.6M in a two-day window—and the demonstrated timing precision in prior SYK sales merit investor attention to whether this signals a shift in her conviction or positioning relative to the company's valuation (trading at a 46.24 P/E).

SYK Chief Legal Officer Robert S Fletcher sells 1,785 shares ($701.6K) at $393.07; stock now down 4.6% from 52-week high.

Fletcher Robert S, VP and Chief Legal Officer of Stryker Corp, sold 1,785 shares (10.5K shares post-transaction) on 2025-08-20 at $393.07, reducing his holdings by 14.6%. The sale occurred near the upper portion of the stock's 52-week range ($337.37–$403.53), with the current price at $384.83 representing a 4.6% decline from the 52-week high. His prior sell at this ticker (2024-05-22) resulted in a 90-day return of +3.0%, meaning the stock rose after the sale, indicating the prior trade was not well-timed for avoiding subsequent gains. The current sale represents routine portfolio activity for a senior executive, with no clear pattern of prescient exit timing evident from his single prior SYK transaction.

Director Ronda Stryker sells 200,000 SYK shares in 8 transactions totaling $75.3M at average $376.45

Director Ronda Stryker executed 8 separate sales totaling 200,000 shares (200.0K shares) for $75,289,655.38 ($75.3M) on 2025-08-06, reducing her holdings by 5.8% to 3,222,108 shares (3.22M shares). The sale prices ranged from $374.99 to $380.63 per share, with a blended average price of $376.45, occurring near the current price of $376.37. At the same-ticker level, Stryker's prior 5 sales at SYK (all conducted on 2025-05-06) showed 0 well-timed outcomes at the 90-day mark, indicating her historical timing decisions at this ticker have not preceded price declines; her cross-ticker track record shows a 30% well-timed rate across 20 prior sells. The scale of this liquidation—a substantial dollar amount representing a meaningful reduction in an already-large executive position—occurs with the stock trading 6.7% below its 52-week high and down 3.4% over 30 days, against a backdrop of strong fundamental metrics (revenue $6.0B, P/E 49.33, annual growth +10.2%).

Director Ronda Stryker sold 200,000 shares for $75.4M; prior 5 SYK sales all well-timed at 90-day mark.

On 2025-05-06, STRYKER RONDA E, a Director at Stryker Corp, executed 6 separate sales totaling 200,000 shares for $75,391,847.90 at a blended average price of $376.96. The transaction reduced her holdings from 3.62M to 3.42M shares (-5.5%). Notably, her prior 5 trades at SYK (all on 2025-01-31) were all well-timed at the 90-day mark, with negative 90-day returns ranging from -4.3% to -5.5%, suggesting a track record of selling before declines at this specific ticker. The current price of $382.46 is 4.4% below the 52-week high ($399.90) and up 13.4% over the past 30 days, indicating the stock has recovered after the 2025-01-31 sales. This filing merits monitoring to assess whether the current May 2025 sale follows the same well-timed pattern observed in her recent SYK transaction history.

Director Stryker sold 201,392 shares (5.2% reduction) for $78,993,068.38 on 2025-01-31

Ronda E. Stryker, a Director at Stryker Corp, executed 6 separate sales on 2025-01-31, divesting 201,392 shares (201.4K shares) for $78,993,068.38 ($79.0M) at prices ranging from $390.90 to $395.60, with a blended average of $392.24. This represented a 5.2% reduction of her pre-transaction holdings (from 3.84M shares to 3.64M shares). The transactions occurred as SYK traded within 2.2% of its 52-week high of $399.90, suggesting the sales occurred at elevated valuations. Her prior 5 sales at SYK (all on 2024-11-05) showed positive 30-day and 90-day returns, with none well-timed at the 90-day horizon—a pattern indicating the stock continued higher after those sales. The company trades at a P/E of 41.52 with $5.5B quarterly revenue and +11.1% annual growth, but the timing and scale of this divestiture warrant scrutiny given the proximity to the 52-week highs and lack of well-timed exits in her same-ticker history.

Stryker CEO Kevin Lobo sells 57.3K shares (57,313 shares) for $21,131,479.29 across 3 transactions on 2024-11-07

Lobo executed 3 separate sales totaling 57,313 shares for $21,131,479.29 at an average price of $368.70, reducing his holdings by 36.4% from 157.3K to 100.0K shares. The sale occurred as the stock trades near its 52-week high of $375.96 with strong recent momentum (30-day: +6.2%, 90-day: +14.7%), and his prior 4 sales at SYK in November 2023 all saw the stock rise over the subsequent 90 days (range +20.3% to +21.4%), meaning none were well-timed. The company remains fundamentally strong with $5.5B quarterly revenue, +11.1% annual growth, and $834.0M net income, though valued at a rich 39.91 P/E. The magnitude and timing of this large open-market sale merit observation against the company's current valuation and recent price strength.